Hassan Sevda, Mumford Lisa, Robinson Susan, Foukanelli Dora, Torpey Nick, Ploeg Rutger J, Mamode Nizam, Murphy Michael F, Brown Colin, Roberts David J, Regan Fiona, Willicombe Michelle
Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.
Imperial College Renal and Transplant Centre, Imperial College Healthcare National Health Service (NHS) Trust, Hammersmith Hospital, London, United Kingdom.
Front Nephrol. 2023 Jul 24;3:1236520. doi: 10.3389/fneph.2023.1236520. eCollection 2023.
Patient Blood Management (PBM), endorsed by the World Health Organisation is an evidence-based, multi-disciplinary approach to minimise inappropriate blood product transfusions. Kidney transplantation presents a particular challenge to PBM, as comprehensive evidence of the risk of transfusion is lacking. The aim of this study is to investigate the prevalence of post-transplant blood transfusions across multiple centres, to analyse risk factors for transfusion and to compare transplant outcomes by transfusion status.
This analysis was co-ordinated via the UK Transplant Registry within NHS Blood and Transplant (NHSBT), and was performed across 4 centres. Patients who had received a kidney transplant over a 1-year period, had their transfusion status identified and linked to data held within the national registry.
Of 720 patients, 221(30.7%) were transfused, with 214(29.7%) receiving a red blood cell (RBC) transfusion. The proportion of patients transfused at each centre ranged from 20% to 35%, with a median time to transfusion of 4 (IQR:0-12) days post-transplant. On multivariate analysis, age [OR: 1.02(1.01-1.03), p=0.001], gender [OR: 2.11(1.50-2.98), p<0.0001], ethnicity [OR: 1.28(1.28-2.60), p=0.0008], and dialysis dependence pre-transplant [OR: 1.67(1.08-2.68), p=0.02], were associated with transfusion. A risk-adjusted Cox proportional hazards model showed transfusion was associated with inferior 1-year patient survival [HR 7.94(2.08-30.27), p=0.002] and allograft survival [HR: 3.33(1.65-6.71), p=0.0008], and inferior allograft function.
RBC transfusions are common and are independently associated with inferior transplant outcomes. We urge that further research is needed to understand the mechanisms behind the outcomes, to support the urgent development of transplant-specific anaemia guidelines.
患者血液管理(PBM)得到世界卫生组织认可,是一种基于证据的多学科方法,旨在尽量减少不适当的血液制品输注。肾移植对PBM提出了特殊挑战,因为缺乏输血风险的全面证据。本研究的目的是调查多个中心移植后输血的发生率,分析输血的危险因素,并按输血状态比较移植结局。
该分析通过英国国民医疗服务体系血液与移植机构(NHSBT)内的英国移植登记处进行协调,在4个中心开展。对在1年期间接受肾移植的患者,确定其输血状态并与国家登记处保存的数据相关联。
720例患者中,221例(30.7%)接受了输血,其中214例(29.7%)接受了红细胞(RBC)输血。各中心接受输血的患者比例在20%至35%之间,移植后输血的中位时间为4(四分位间距:0 - 12)天。多因素分析显示,年龄[比值比(OR):1.02(1.01 - 1.03),p = 0.001]、性别[OR:2.11(1.50 - 2.98),p < 0.0001]、种族[OR:1.28(1.28 - 2.60),p = 0.0008]以及移植前依赖透析[OR:1.67(1.08 - 2.68),p = 0.02]与输血相关。风险调整后的Cox比例风险模型显示,输血与患者1年生存率较低[风险比(HR)7.94(2.08 - 30.27),p = 0.002]和同种异体移植物生存率较低[HR:3.33(1.65 - 6.71),p = 0.0008]以及同种异体移植物功能较差相关。
红细胞输血很常见,且与较差的移植结局独立相关。我们敦促需要进一步研究以了解这些结局背后的机制,以支持紧急制定针对移植的贫血指南。